Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7760 · 2 trials · 2 indications
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.
To evaluate the safety of AZD7760 compared with placebo as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (AZD7760 Dose A) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose A on Day 1. |
| Cohort 2 (AZD7760 Dose B) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose B on Day 1. |
| Pooled Placebo | PLACEBO_COMPARATOR | Participants receive an IV infusion of matching placebo on Day 1. |
| Phase I: AZD7760 Dose A | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1. |
| Phase I: AZD7760 Dose B | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1. |
| Phase I: AZD7760 Dose C | EXPERIMENTAL | Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1. |
| Phase I: Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo on Day 1. |
| Phase IIa: AZD7760 Dose D and Placebo | EXPERIMENTAL | Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91. |
| Phase IIa: AZD7760 Dose E | EXPERIMENTAL | Participants will receive AZD7760 Dose E on Day 1 and Day 91. |
| Phase IIa: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo on Day 1 and on Day 91. |
| Name | Type | Description |
|---|---|---|
| AZD7760 | DRUG | Participants will receive AZD7760 via IV infusion. |
| Placebo | OTHER | Participants will receive matching placebo via IV infusion. |
Inclusion Criteria: * Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range of ≥ 18.0 to ≤ 30.0 kg/m2 (inclusive) at screening. * Healthy Japanese participants with no clinically significant concomitant diseases or medications. Exclusion Criteria: * Known hypersensitivity to any component of ...